SENSITIVITY TO CONVENTIONAL CHEMOTHERAPEUTIC DRUGS ACCORDING TO ARID1A DEFICIENCY OF OVARIAN CLEAR CELL CARCINOMA AND ENDOMETRIOID CARCINOMA CELLS

被引：0
|
作者：
Kuroda, T. [1 ,2 ]
Ogiwara, H. [1 ]
Takahashi, K. [1 ,2 ]
Sasaki, M. [1 ]
Yoshida, H. [3 ]
Kato, T. [4 ]
Okamoto, A. [2 ]
Kohno, T. [1 ]
机构：
[1] Natl Canc Ctr, Div Genome Biol, Res Inst, Tokyo, Japan
[2] Jikei Univ, Dept Obstet & Gynecol, Sch Med, Tokyo, Japan
[3] Natl Canc Ctr, Dept Pathol & Clin Labs, Tokyo, Japan
[4] Natl Canc Ctr, Dept Gynecol, Tokyo, Japan
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2018年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IGCS8-0330
引用
收藏
页码：180 / 180
页数：1
相关论文
共 50 条
  • [1] The ARID1A pathway in ovarian clear cell and endometrioid carcinoma, contiguous endometriosis, and benign endometriosis
    Chene, Gautier
    Ouellet, Veronique
    Rahimi, Kurosh
    Barres, Veronique
    Provencher, Diane
    Mes-Masson, Anne Marie
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2015, 130 (01) : 27 - 30
  • [2] ARID1A gene silencing reduces the sensitivity of ovarian clear cell carcinoma to cisplatin
    Lyu, Changshuai
    Zhang, Yinglan
    Zhou, Xingnan
    Lang, Jinghe
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2016, 12 (06) : 4067 - 4071
  • [3] Evidence Supporting Endometriosis as a Precursor of Ovarian Clear Cell and Endometrioid Carcinoma Based on Expression of ARID1A
    Ayhan, A.
    Mao, T-L
    Wu, C-H
    Ogawa, H.
    Futagami, M.
    Mizukami, H.
    Yokoyama, Y.
    Kurman, R. J.
    Shih, I-M
    LABORATORY INVESTIGATION, 2012, 92 : 259A - 259A
  • [4] Evidence Supporting Endometriosis as a Precursor of Ovarian Clear Cell and Endometrioid Carcinoma Based on Expression of ARID1A
    Ayhan, A.
    Mao, T-L
    Wu, C-H
    Ogawa, H.
    Futagami, M.
    Mizukami, H.
    Yokoyama, Y.
    Kurman, R. J.
    Shih, I-M
    MODERN PATHOLOGY, 2012, 25 : 259A - 259A
  • [5] ARID1A expression in ovarian clear cell carcinoma with an adenofibromatous component
    Nishikimi, Kyoko
    Kiyokawa, Takako
    Tate, Shinichi
    Iwamoto, Masami
    Shozu, Makio
    HISTOPATHOLOGY, 2015, 67 (06) : 866 - 871
  • [6] Clinicopathological Significance of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma
    Maeda, D.
    Mao, T-L
    Fukayama, M.
    Wang, T-L
    Shih, I-M
    MODERN PATHOLOGY, 2011, 24 : 259A - 259A
  • [7] Genome-wide DNA methylation in relation to ARID1A deficiency in ovarian clear cell carcinoma
    Li, Shang
    Meersma, Gert Jan
    Kupryjanczyk, Jolanta
    de Jong, Steven
    Wisman, G. Bea A.
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [8] Clinicopathological Significance of Loss of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma
    Maeda, Daichi
    Mao, Tsui-Lien
    Fukayama, Masashi
    Nakagawa, Shunsuke
    Yano, Tetsu
    Taketani, Yuji
    Shih, Ie-Ming
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2010, 11 (12): : 5121 - 5129
  • [9] Clinicopathological Significance of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma.
    Maeda, D.
    Mao, T-L
    Fukayama, M.
    Wang, T-L
    Shih, I-M
    LABORATORY INVESTIGATION, 2011, 91 : 259A - 259A
  • [10] The role of chromatin remodeler protein ARID1a in ovarian clear cell carcinoma
    Lakshminarasimhan, Ranjani
    Andreu-Vieyra, Claudia
    Lawrenson, Kate
    Gayther, Simon A.
    Jones, Peter A.
    Liang, Gangning
    CANCER RESEARCH, 2016, 76
12345